webinar register page

Webinar banner
Biologics & Biosimilars Webinar: Insights for Patients & Physicians

01:32:00

Aug 18, 2020 11:40 AM

Webinar logo
* Required information
Loading

Speakers

Sarah Yim
Acting Director @Office of Therapeutic Biologics and Biosimilars/OND/CDER at FDA
Sarah Yim, M.D. is the Director of the Office of Therapeutic Biologics and Biosimilars, in CDER’s Office of New Drugs (OND), FDA. Prior to that, she spent 2 years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years in various roles in rheumatology drug review in OND. She received her undergraduate degree from Stanford University, her Doctor of Medicine degree from the Uniformed Services University of Health Sciences, and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), at the National Institutes of Health.
Emanuela Lacana
Deputy Director @Office of Therapeutic Biologics and Biosimilars at FDA
Emanuela Lacana, PhD, is the Deputy Director of the Office of Therapeutic Biologics and Biosimilars, in CDER’s Office of New Drugs (OND), FDA. Prior to that, she spent 18 years in various product quality review and policy roles in CDER’s Office of Biotechnology Products. She received her Master and PhD degree from the University of Milan, Italy. She completed postdoctoral fellowship at the National Institutes of Health, where she conducted research on T cell apoptosis and development, and Georgetown University, where she studied cellular signaling mediated by sphingolipids.
Dr. Jonathan Kay
Professor of Medicine and Population and Quantitative Health Sciences @University of Massachusetts Medical School
Jonathan Kay, MD, is Professor of Medicine and Pop ulation and Quantitative Health Sciences and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology at the University of Massachusetts Medical School in Worcester, where he directs Clinical Research in the Division of Rheumatology. He received his medical degree from the University of California School of Medicine in San Francisco, California. He then completed an internship and residency at the Hospital of the University of Pennsylvania in Philadelphia and fellowships in rheumatology and immunology at the Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts. Over the past decade, he has been involved in the development of biosimilars to treat rheumatic diseases. Dr. Kay lectures internationally and is the author of more than 230 publications and book chapters.